Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.

Onco Targets Ther · 2016 · PMC4734822 · PMID 26869800

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

45 Although the mutational frequency of NRAS is very low, there is a strong trend toward a negative response to anti-EGFR antibodies therapy in populations for wild-type KRAS/mutational NRAS.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.